Start-up Dezima Taking on Big Pharma in CETP Inhibition
By Cormac Sheridan
Tuesday, January 22, 2013
Newly established Dutch start-up Dezima Pharma BV in-licensed what it considers a best-in-class cholesteryl ester transfer protein inhibitor, DEZ-001 (formerly TA-8995), from Mitsubishi Tanabe Pharma Corp. and is planning to move the cholesterol-lowering drug into a Phase II trial involving more than 400 patients in the coming months.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.